EEF2K and cancer: eEF-2 kinase, a critical negative modulator of protein synthesis, has been reported to regulate the sensitivity of cancer cells to several therapeutic drugs, including MK-2206, deoxyglucose, velcade, curcumin, TNF-related apoptosis-inducing ligand and temozolomide [13–17].